drugset / Trial / NCT00116467

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

NCT00116467 ↗

Phase 2 Completed 55 enrolled Cell Genesys
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).

Timeline

Start
2001-03
Primary completion
—
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject GVAX leukemia vaccine Vaccine — —